About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Genetic Susceptibility to Kidney Cancer | Clinical Trials | Clareo Health

Back to clinical trial search

TERMINATEDNCT00854022

Genetic Susceptibility to Kidney Cancer

This study will further the understanding of the genetic events leading to the development of RCC.

Lead sponsor: Baylor College of Medicine•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Baylor College of Medicine

Collaborators

M.D. Anderson Cancer Center

This study will further the understanding of the genetic events leading to the development of RCC; explore the genetic basis for genetic instability and how it affects cancer risk; and eventually provide a means of identifying a subgroup of individuals who are most likely to develop RCC. Such individuals may then be targeted for intervention programs such as chemoprevention or dietary modification.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Adult patients of any ethnicity or sex, who have a been diagnosed with possible Renal Cell Carcinoma within the past year.

Exclusion Criteria

•Must not have received chemotherapy, biological therapy or radiation therapy in the 6 months preceding enrollment will
•Must not have had RCC, or metastatic RCC,
•Must not have had a renal transplantation

Related studies

RECRUITINGEARLY Phase 1

The Safety and Efficacy of Allogeneic CD70 CAR-T Therapy in Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

NCT07645690 · Unresectable or Metastatic Clear Cell Renal Cell Carcinoma

RECRUITINGPhase 3

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720 · Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), and more

RECRUITINGPhase 2

Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC

NCT06863311 · Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, and more

TDM for Optimized Outcome in Patients With mRCC.

NCT04659343 · Kidney Cancer, Renal Cell Carcinoma Metastatic, and more

RECRUITINGPhase 3

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain

NCT06500455 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 25, 2020Terms

Trial snapshot

StatusTERMINATED

Phase—

Enrollment6

Start dateJul 2008

Last updatedFeb 25, 2020

Condition

Renal Cell Carcinoma

Locations shown

MD Anderson Cancer Center

Houston, Texas

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 25, 2020Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions